Ready for a wave of big biotech acquisitions and mergers? That, and other industry-transforming events, are likely to happen for biotech in the near term, according to consulting firm Ernst & Young. Not only that, but given the hunger for experimental therapies from innovative biotech companies, valuations are likely to run high, keeping the industry insulated from the overall downturn in the U.S. economy. Article